DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLUCAGEN

Clinical Trials for Glucagen

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00745186	Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers	Completed	Hospira, Inc.	Phase 1	The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
NCT00747968	The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	Completed	Aarhus University Hospital	Phase 2/Phase 3	30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00747968	The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	Completed	Eli Lilly and Company	Phase 2/Phase 3	30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00747968	The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	Completed	University of Aarhus	Phase 2/Phase 3	30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT01185119	Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET	Completed	University of Aarhus	Phase 2/Phase 3	10 healthy men will be PET-scanned (CNS) twice in random order with infusions of placebo or Native GLP-1 during hyperglycemic clamp to uncover the metabolic effects of GLP-1 in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT01994746	Effectiveness and Safety of Intranasal Glucagon for Treatment of Hypoglycemia in Adults	Completed	Eli Lilly and Company	Phase 3	The primary objective of this study is to assess the effectiveness and safety of 3 mg glucagon (AMG504-1) administered as a puff into the nose compared with commercially-available glucagon given by injection.
NCT01994746	Effectiveness and Safety of Intranasal Glucagon for Treatment of Hypoglycemia in Adults	Completed	Jaeb Center for Health Research	Phase 3	The primary objective of this study is to assess the effectiveness and safety of 3 mg glucagon (AMG504-1) administered as a puff into the nose compared with commercially-available glucagon given by injection.
Trial ID	Title	Status	Sponsor	Phase	Summary